勘误：与T细胞衔接器相比，靶向BCMA的双特异性NK细胞衔接器具有更强的抗肿瘤作用且产生的促炎细胞因子更少。
Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
作者信息
Xiao Xinghui, Cheng Ying, Zheng Xiaodong, Fang Yuhang, Zhang Yu, Sun Rui, Tian Zhigang, Sun Haoyu
机构信息
Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Institute of Immunology, University of Science and Technology of China, Hefei, China.
出版信息
Front Immunol. 2024 Jan 16;15:1365027. doi: 10.3389/fimmu.2024.1365027. eCollection 2024.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2023.1113303.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fimmu.2023.1113303。]
相似文献
1
Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.勘误：与T细胞衔接器相比，靶向BCMA的双特异性NK细胞衔接器具有更强的抗肿瘤作用且产生的促炎细胞因子更少。
Front Immunol. 2024 Jan 16;15:1365027. doi: 10.3389/fimmu.2024.1365027. eCollection 2024.
2
Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.双特异性自然杀伤细胞衔接器靶向 BCMA 比 T 细胞衔接器产生更强的抗肿瘤作用和更少的促炎细胞因子。
Front Immunol. 2023 Apr 11;14:1113303. doi: 10.3389/fimmu.2023.1113303. eCollection 2023.
3
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.IBI379，一种新型的 B 细胞成熟抗原/CD3 双特异性 T 细胞衔接子，在多发性骨髓瘤的多个临床前模型中显示出高抗肿瘤疗效。
Cancer Lett. 2022 Jun 28;536:215663. doi: 10.1016/j.canlet.2022.215663. Epub 2022 Apr 4.
4
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.一种新型的 BCMA/CD3 双特异性 T 细胞衔接子，用于治疗多发性骨髓瘤，可在体外和体内诱导选择性裂解。
Leukemia. 2017 Aug;31(8):1743-1751. doi: 10.1038/leu.2016.388. Epub 2016 Dec 27.
5
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.一种用于治疗多发性骨髓瘤的新型BCMA/CD3双特异性T细胞衔接器在体外和体内均能诱导选择性裂解。
Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.219. Epub 2017 Jul 28.
6
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.双特异性和三特异性免疫细胞衔接器在血液系统恶性肿瘤免疫治疗中的应用。
J Hematol Oncol. 2023 Jul 27;16(1):83. doi: 10.1186/s13045-023-01482-w.
7
T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.T细胞衔接抗体可使T细胞控制小鼠体内的HBV感染并靶向HBsAg阳性肝癌。
J Hepatol. 2021 Nov;75(5):1058-1071. doi: 10.1016/j.jhep.2021.06.022. Epub 2021 Jun 23.
8
A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell-Based Cancer Immunotherapy.一种可变形的超分子双特异性细胞衔接子，用于增强自然杀伤细胞和 T 细胞为基础的癌症免疫疗法。
Adv Mater. 2024 Jan;36(3):e2306736. doi: 10.1002/adma.202306736. Epub 2023 Dec 1.
9
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.NK 细胞衔接双特异性抗体治疗癌症的原则和临床现状。
Hum Vaccin Immunother. 2023 Aug;19(2):2256904. doi: 10.1080/21645515.2023.2256904. Epub 2023 Sep 29.
10
Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.分泌αCD133-αCD3 双特异性 T 细胞衔接器的 T 细胞对胆管癌的抗肿瘤活性。
PLoS One. 2022 Mar 21;17(3):e0265773. doi: 10.1371/journal.pone.0265773. eCollection 2022.
Zotero 插件